Figure 1From: Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain Markov model diagram. Detailed legend: GP40+: general population aged 40 and above, RCC1 to RCC10: 10-year cohort of RCC prevalence, ARCC: advanced RCC patients, PARCC/D: post-advanced RCC patients or deathBack to article page